International Journal of
INTELLIGENT SYSTEMS AND APPLICATIONS IN ENGINEERING
ISSN:2147-6799 www.ijisae.org Original Research Paper

Engineering Resilient Supply Chains for Critical Healthcare Manufacturing During Global Disruptions

Madhav Jayeshkumar Pandya

Abstract: Healthcare manufacturing supply chains are the operating system for global public health systems. Recent disruptions have shown that existing lean systems, which are designed to be most efficient, are not strong enough to handle simultaneous increases in demand, supplier backlog, regulatory constraints, and logistics constraints all at the same time. These limitations expose structural flaws in current supply chains. This article considers the structural characteristics and behavior of supply chain resilience in healthcare manufacture and reviews approaches to supply chain structural failure modes, supplier network optimization, predictive risk analytics, and integrated production continuity. A Resilient Manufacturing Network Framework synthesizing supply chain engineering and real-time analytics is proposed to enable proactive and reactive disruption management. This article demonstrates that resilience cannot be achieved through any single intervention in the supply chain landscape but instead requires the coordinated deployment of diversified supplier architectures, anticipatory risk intelligence, responsive production planning systems, and a shared digital backbone.

Keywords: *Supply Chain Resilience, Healthcare Manufacturing, Disruption Management, Predictive Risk Analytics, Supplier Diversification, Production Continuity*

1. Introduction

Healthcare manufacturing supply chains are the organizations involved with the reliable end-to-end manufacturing and distribution of the pharmaceuticals, diagnostics, and medical devices upon which patient care depends [19]. They are sometimes referred to as the operational backbone of any public health system and have been found to be vulnerable to global shocks. Epidemic outbreaks, geopolitical tensions, and logistics failures have demonstrated that supply chains optimized for cost efficiency under stable conditions are structurally ill-equipped to absorb sudden, high-magnitude shocks [10]. The consequences are not abstract. In developing countries, counterfeit medicines have been able to exploit the weaknesses in the supply chain to constitute as much as 30% of the pharmaceutical market, compared to less than 1% in developed countries. This may therefore be used as an indicator for the public health burden of supply chain fragility [21]. Figure 3 illustrates this disparity in counterfeit medicine prevalence across market contexts, drawing on data from Alfaouri et al. [21]. The contrast between the sub-1% rate in high-income markets and the up-to-30% rate in lower-income markets underscores that supply chain design failures are not distributed evenly, they are borne disproportionately by populations with the fewest alternative sources of essential medicines. Despite better awareness of the dangers, a gap in application remains between the proposed resilience constructs and the architectures that healthcare manufacturers could deploy. Existing literature has tended to discuss individual resilience levers (such as supplier diversification and inventory buffers) in isolation, rather than a system-level design. Thus, this paper will present systemic vulnerabilities of healthcare supply chains, diversification strategies from the supply-base engineering perspective, predictive risk analytic solutions, the role of digital infrastructure in orchestrating crisis response, and a Resilient Manufacturing Network Framework that seeks to support the continuity of production in the event of an acute global disruptor.

Independent Researcher, USA

2. Structural Vulnerabilities in Healthcare Supply Chains

2.1 Supplier Concentration and Geographic Risk

One of the most persistent architectural risks for healthcare manufacturers is that critical raw material supply concentrates in certain geographies. For example, some pharmaceutical precursors, specialty resins for device manufacturing, and microbiological growth media are produced in a limited number of facilities globally. One specific mechanism for supply chain failure is that concentrating suppliers increases the chance that a localized disruption spreads downstream in a failure cascade, turning a local disruption into a systemic failure that affects many downstream processes [8]. For many inputs to production, a single site or country supplies the majority of the world market so that environmental, geopolitical, or regulatory forces at that origin immediately reverberate down the supranational supply chain. The limited multi-tier visibility into supplier dependency structures makes the problem even worse. Results of the systematic literature review of geopolitically induced supply chain disruptions revealed that upstream concentration risks are often invisible to manufacturers further down the supply chain, as tier-two and tier-three related supply chain contracts are seldom scrutinized to the same extent [22]. Even if a healthcare manufacturer believes it has a diverse supplier base, all suppliers may have the same upstream source at multiple tiers. So mapping out second- and third-tier supplier relationships proves important and is not simply a best practice for understanding one's risk exposure on the component level. Fu Jia et al., in their work on supply chain agility frameworks, argued that visibility should extend beyond the immediate supplier to the entire upstream supply chain for it to be genuine [1].

Geographic concentration is also associated with regulatory risk. During public health emergencies, regulatory authorities in different countries may put restrictions on exports and prioritize certain products. This can stop the flow of goods across national borders, even if there are already commercial contracts in place. However, supply chains can be designed to cross regulatory boundaries intentionally, creating a structural hedge against regionally targeted regulatory interventions. However, coordination mechanisms must manage the additional complexity that such architectures require [16].

2.2 Regulatory Constraints on Supply Flexibility

This regulatory environment creates a different regulatory environment for the healthcare manufacturing supply chain that slows down and does not allow agile reactions as the material, manufacturing process, and quality must match the regulatory submissions. The European Medicines Agency Good Manufacturing Practice (GMP) guidelines require the qualification of suppliers, the validation of processes, the traceability of materials, and the assessment of the processes and resulting products from all suppliers in the supply chain [3]. However, these requirements for product safety and efficacy are also responsible for the comparatively slow adaptation of the supply chain.

Qualifying a new supplier or alternative source of raw materials can be a lengthy process, as it requires demonstrating their equivalence through analytical, manufacturing, and sometimes stability studies; if this work has not been done proactively, avoiding prolonged disruption during an incident may be challenging. The regulatory framework defined by the U.S. Food and Drug Administration's Drug Supply Chain Security Act further codifies traceability and verification requirements that affect the speed of operational availability for alternative supply sources [17]. This creates an asymmetry that favors supply disruptions over alternatives, for example, days versus quarters for operational availability.

Thus, it makes sense to pre-competitively qualify potential suppliers. If the company has a portfolio of qualified alternative suppliers, it can adapt to changing conditions and not be delayed by regulatory requirements if the supply capacity needs to be increased. Multi-objective optimization studies of the resilience of the pharmaceutical supply chain have shown that pre-qualifying second sources of supply, thus investing to avoid a disruption, has an important advantage over reactive qualification in minimizing production loss from disruptions [18]. WHO surveillance data show that failing to qualify suppliers results in supply risk and reduced product quality [4].

2.3 Infrastructure Specialization and Capacity Constraints

Many health care facilities, especially those that have dedicated or specialized infrastructure for one particular product, formulation, or sterilization method, will prioritize efficiency of normal operations over flexibility to respond to unexpected increases in demand. For example, parenteral drug production and diagnostic reagent production may be performed by the same organization, but a parenteral drug production facility is not easily repurposed to make diagnostic reagents. Infrastructure specialization is another dimension of healthcare supply chain vulnerability that Claudia Piffari et al. identify as often overlooked, but one that impedes the network-level flexibility necessary for resilience in the healthcare supply chain [19]. The practical upshot of all of this is that limits to capacity in surge demand are not only a question of how much throughput can be produced but also how much of what type. The U.S. Department of Health and Human Services (HHS) Thorough Framework for Supply Chain Resilience cites production-capacity flexibility as a dimension of resilience. Vulnerability assessments must not only determine whether production capacity exists but also whether that capacity may be redirected or repurposed in response to disruption [23]. To address this challenge, it is needed to invest in modular or flexible manufacturing architectures and networked mapping of latent production capabilities in multi-site manufacturing organizations. The effects of the intrinsic rigidity of capacity were discussed by Pankaj Bhardwaj et al. based on their scoping review of literature regarding supply chain resilience in the public healthcare system. They concluded that when decisions are made under predictable conditions and do not take resilience aspects into account for their infrastructure capital planning, resilience is achieved through the scenario-weighted assessment of capacity flexibility to disruptions [20].



Figure 1: Structural Vulnerability Map [3, 19, 20, 22]

3. Supplier Network Engineering and Diversification

3.1 Principles of Network Diversification Architecture

Supplier diversification is most effective if it is designed as a deliberate network architecture rather than implemented as a loose response to a failure of previous suppliers and across multiple dimensions. Geographic diversification reduces regional dependencies, while technological diversification reduces process dependencies by sourcing from suppliers that manufacture an equivalent material using different production processes. David Simchi-Levi et al. wrote that, in their comparison of models of supply chain competition and collaboration, network designs that appear disadvantageous using steady-state cost metrics possess a high resilience value using disruption probability-weighted performance metrics [6].

Organizational diversification that prevents reliance on suppliers with the same ownership or infrastructure protects against systemic risks of failure that could not be fully understood through a purely commercial lens. As Fu Jia et al. write, for supply chain agility, essential to respond to disruptions, multiple suppliers with de facto independent operational dependencies are required; sharing infrastructure, enterprise resources, or logistics providers would negate the apparent advantages of nominal diversification [1]. A disciplined supplier segmentation model is important to design efficiently across these dimensions. Not all inputs have the same risk profile, and resources to qualify and maintain multi-source supply relationships are finite.

Risk-tiered supplier segmentation ranks supplier materials based on their criticality. Material criticality itself is a function of the product's functional irreplaceability and of the operational severity of the event of material shortage. Accordingly, a study by the McKinsey Global Institute on resilience and rebalancing in global value chains showed that companies with explicit risk-tiered supplier segmentation were able to recover from an event of supply chain disruption much faster than those with a homogeneous supplier base [16]. Sodhi and Tang further established that the optimal level of supply chain risk mitigation Investment is proportional to the product of disruption probability and consequence severity, which provides a framework for rigorously prioritizing resilience investments across a supplier portfolio [25].

3.2 Supplier Risk Assessment and Continuous Monitoring

A diversified supplier portfolio requires active management of risk to retain its benefits. Supplier qualification, however, is a point-in-time analysis. To be resilient, companies also need to monitor supplier viability with respect to financial, operational, quality, and geopolitical dimensions. Maciel M. Queiroz et al.'s structured literature review on the impact of epidemic outbreaks on supply chains found that supplier disruptions during the COVID-19 pandemic often provided early warning signals for downstream manufacturers (lead time increases and raw material pricing variations) weeks before supply disruptions occurred [10]. The results highlight the importance of real-time monitoring systems to detect and alert as soon as these signals are generated.

Financial metrics such as credit ratings, working capital, and capital expenditure can be early indicators that suppliers are resource-squeezed and might cause degradation of production reliability over time. Operational metrics such as on-time in-full delivery rates, lead time variability, and yield from incoming quality inspections reflect the current performance of suppliers. A key leading indicator for a supply disruption is the trending quality data, as quality metrics may be the first trend to show deterioration prior to a disruption. WHO also indicated that evidence of overcrowded supplier capacity may correlate with low-quality medical products, based on WHO global surveillance data on substandard medical products [4]. This reinforces the importance of monitoring quality performance.

Signals from outside the organization, such as regulatory interventions, natural disasters, and political problems in major supplier origin countries, can be observed. According to C. Lopez et al. in the systematic review, geopolitical disruptions to supply chains are often preceded by observable macro-level signals, which supply risk monitoring systems can detect if they are configured to ingest external data sources [22]. Integrating these streams into a single supplier risk platform means procurement and supply chain teams can maintain a current and complete profile of supplier risk exposure across the company's entire supplier base.

Risk dimension	Key indicators	Data sources	Monitoring frequency	Escalation threshold
Financial health	Credit metrics, working capital trends, capex patterns	Credit agencies, financial disclosures	Quarterly	Credit downgrade or quarter loss trend
Operational performance	On-time delivery rate, lead time variability, yield trends	ERP / procurement system, logistics data	Weekly	lead time increase

Quality performance	Incoming inspection failure rate, deviation frequency, CAPA trends	Incoming quality records, WHO surveillance data	Per shipment	Rejection rate exceeding established baseline
Geographic risk	Natural disaster alerts, export restriction notices, conflict proximity	Geopolitical risk feeds, regulatory bulletins	Continuous	Any Level 3+ geopolitical event in supplier region
Capacity availability	Utilization rate, order acceptance ratio, sub-tier stress signals	Market demand indices	Monthly	High utilization
Regulatory compliance	Inspection outcomes, warning letters, license status	FDA DSCSA database, EMA GMP records	Monthly	Any regulatory action or import alert issued

Table 1: Supplier Risk Assessment Dimensions [1, 4, 10, 22]

3.3 Strategic Inventory Positioning

Supplier diversification and risk monitoring reduce, but cannot remove, the risk of supply disruptions. Strategic inventory buffers absorb supply variability and provide operational time for alternatives to be implemented when a disruption is underway. Early work by Paul H. Zipkin on inventory theory established that safety stock is required for demand uncertainty and lead time uncertainty (each of which is increased with global supply chain disruptions) and, in healthcare, also for product perishability [11]. Steven Nahmias' review of perishable inventory theory concluded that managers should explicitly model both expiration and stockout risk when managing safety stock. This requirement is naturally applicable in the case of managing inventories of pharmaceuticals and biological products [12].

The amount of inventory buffers needed is a function of lead time variability, forecast error, and the time to fulfill an additional source of supply. If supplier lead times are long, demand volatility is high, or qualifying a new supplier is time-consuming, safety stock levels will generally be higher. Distributed inventory buffers are less susceptible to distribution failure events that are confined to one location or a small cluster of locations (regional distribution nodes). According to the World Economic Forum's Elaine Dezenski, one of the most impactful yet least risky decisions manufacturers can make to increase supply chain resilience is to distribute inventory within the existing buffer network [14].

You can weigh the costs of carrying safety stock against the costs of lost revenue, lost reputation, and public health impacts from shutting down production. In their multi-objective optimization framework for managing pharmaceutical supply chain disruptions, Badejo and Ierapetritou showed that including inventory positioning as a decision variable in resilience optimization improved expected performance under disruption scenarios despite the cost of carrying stock [18].

4. Predictive Risk Analytics for Proactive Disruption Management

4.1 Architecture of Predictive Risk Intelligence Systems

Predictive risk analytics systems are designed to identify signals of disruption soon after they become apparent but before they stop production. Their primary value lies in accelerating the organizational response window. Ivanov and Dolgui demonstrated in their journal article on digital supply chain twins for Industry 4.0 that the ability to simulate disruption propagation in real time represents a significant advancement in supply chain risk management, enabling organizations to shift from reactive to anticipatory operational postures [2]. This capability requires an architecture able to ingest heterogeneous signals, derive structured insights, and translate those insights into operational actions.

These systems internally gather operational data, including supplier performance, inventory levels, production plans, and logistics tracking. They also analyze the status of transportation networks, regulatory databases, commodity markets, and geopolitical risk feeds from an external perspective. The range of data sources is by design, but they cannot provide enough early warning for all types of healthcare supply chain disruption. In terms of disaster scenarios, Vikas Kumar et al. reported that AI risk platforms that use operational and external data have a much higher disruption detection rate than those that rely solely on operational data when applied to healthcare supply-chain networks [5].

The analytical processing layer is where statistical and machine learning models identify patterns that could indicate an impending risk, such as time-series anomaly detection, which may flag unusual inflections in lead time from suppliers and inventory consumption before thresholds are breached. Raji Ramakrishnan Nair et al. showed that applying Long Short-Term Memory networks to healthcare supply chain data could generate disruption probabilities sufficiently ahead of time to make inventory and supplier changes and outperform customary time-series forecasting methods in conditions of volatile demand [24]. The output layer of the ANN provides risk indicators and recommended actions, and presents them in formats that ease rapid decision-making by supply chain planners, procurement managers, and executives.

4.2 Key Risk Indicators and Signal Interpretation

The pursuit to identify risk indicators that provide an early warning rather than a post hoc confirmation is a central issue in risk analytics. The diagnostic value of a risk indicator can be assessed by its lead time advantage (relative to the disruption), specificity (to separate real risks from normal operational variability), and sensitivity (to capture as many risk events as possible). Another study on applications of AI within operations management found that feature selection has a deep impact on the use of machine learning models. For example, in a supply chain application, the variables included in the machine learning models should be leading indicators (rather than lagging indicators) of what is to be predicted [9]. Supplier lead time variability is one of the most operationally insightful leading indicators, as any sustained increases in lead times to delivery, even within acceptable delivery windows, often indicate production bottlenecks at supplier facilities. Queiroz et al. indicate that, due to epidemic-driven supply chain disruptions, most of the reported supply failure cases had lead time inflation as a precursor, which provided a detectable early warning window that was not exploited by reactive monitoring systems [10]. Indicators of transportation infrastructure strain, such as port congestion or fluctuations in freight rates, may indicate logistical disruptions for supply chains.

Risk indicator	Operational impact	Detection method
Supplier lead time variability	Potential material shortages	Time-series anomaly detection: LSTM forecasting
Transportation delays	Distribution disruptions	Port congestion index, freight rate monitoring
Demand signal volatility	Demand planning uncertainty	ML-based need classification: sentiment analysis
Inventory aging	Increased expiration risk	RFID-based real-time tracking; shelf-life monitoring
Capacity utilization	Production bottlenecks	Digital twin simulation; real-time MES data
Geopolitical risk signals	Cross-border material flow restriction	External news and regulatory feed monitoring

Table 2: Supplier Risk Assessment Dimensions [2, 5, 10]

These changes also must be interpreted in context: a temporary increase in lead time due to a logistics bottleneck means something different than an increase due to reduced production. Kumar et al. proposed that AI-based risk frameworks should be able to classify the type of disruption, since demand, supply, and logistics-based risks have different mitigation strategies [5]. In another work, a multistep ML framework was proposed that involves need classification, sentiment analysis, and prediction of crisis location, achieving 76% accuracy in location prediction and 75% precision in urgent need prediction. Thus, AI-driven signal classification can be operationally useful in risk analytics systems for various healthcare supply chain environments [5]. Risk analytics systems also perform well when contextual variables, in addition to observed signal information, can tailor reaction intensity.

4.3 Scenario Modeling and Response Simulation

Beyond real-time monitoring of risk, predictive analytics or scenario modeling capability enables supply chain teams to assess the effects of various disruption scenarios on operations. Ivanov and Dolgui's digital twin framework addresses this capability, showing that supply chain digital twins can be used to stress-test network configurations against scenarios of disruptions that go beyond historical experience, providing a basis for resilience investment decisions that cannot be derived from historical performance data alone [2]. The scenarios are constructed by identifying plausible disruption events with respective probabilities and severities, which are then propagated through network models containing information on the dependencies between materials, suppliers, production facilities, and distribution nodes.

Each scenario simulation yields an impact profile in terms of projected inventory depletion, production capacity shortfall, and estimated financial exposure, which may be considered in formulating contingency strategies. Pre-defined response playbooks guide specific actions to take in the event of particular 'high impact, low likelihood' scenarios. Piffari et al. concluded in their framework for managing resilience in the healthcare supply chain that scenario-based preparedness, in the form of pre-validated response protocols, for plausible disruption scenarios is the single strongest predictor of recovery rates following disruption events [19]. When such conditions arise in a real-world incident, real-time monitoring signals will allow the organization to take the pre-approved action rather than react under time pressure.

5. Integrated Crisis Response and Digital Infrastructure

5.1 Crisis Response Planning Architecture

Resilient supply chains require governance and business processes that will translate analytical understanding into coordinated action across multiple functional domains of an enterprise. Crisis response planning provides a decision framework for coordinating procurement, manufacturing, logistics, quality, and commercial operations as a single, unified enterprise-level response to a disruption event. In the view of Christopher and Peck, the absence of cross-functional integration has been identified as a primary failure mode in supply chain crisis response, and organizations with formal, pre-exercised coordination structures consistently outperform those relying on improvised coordination during active disruptions [7].

Good crisis response frameworks also have defined activation thresholds that link to the risk indicators set at the predictive analytics layer. Delays in escalation from the monitoring to crisis response stage due to uncertainty about the right moment to initiate the escalation are the biggest when a fast response is critically needed. Protocols for escalation can eliminate the uncertainty, making the crisis response automatic irrespective of what personnel might be on duty during a disruption. Bhardwaj et al. pointed out in their scoping review that in public health care supply systems with multiple institutional actors that have different goals, formalized escalation pathways, especially those based on quantitative trigger thresholds, are particularly important [20].

When the crisis response structures are created, a chain of command and communications plan is required; this includes allocating crisis leaders for each supply chain domain in cross-functional crisis response teams and allocating responsibilities for response activities. Unclear decision authority during disruptions is often identified as a challenge to effective pharmaceutical supply chain management across multiple regulatory jurisdictions, particularly in root-cause analysis of disruption incidents in supply chains. Unclear decision authority makes the already challenging lack of coordination across organizations and regulatory jurisdictions in the pharmaceutical supply chain even worse [21].

5.2 Digital Supply Chain Control Towers

Digital supply chain control towers provide technology infrastructure to enable both continuous risk monitoring and to support crisis response. Digital supply chain control towers integrate data from supplier management, manufacturing execution, warehouse management, and transportation management into a single view of operations. From a theoretical viewpoint, Ivanov and Dolgui's digital twin architecture assumes real-time data integration across all nodes in the supply chain structure to establish a digital twin, which is the precondition for anticipatory disruption management in how resilient supply chains operate [2]. Integration is across horizontal (all supply chain levels) and vertical (from operational to planning and executive decision-support) dimensions.

Control tower dashboards include information and key performance indicators. These may include metrics such as inventory availability, supplier on-time delivery, production plan adherence, and distribution network performance. The primary value of dashboards is the visibility they provide and how quickly deviations can be detected and escalated. A key enabling technology for this infrastructure is radio frequency identification (RFID). This allows the tracking of goods in real time and provides accurate inventory data by minimizing supply network discrepancies. This finding is supported by The 80% inventory inaccuracy reduction associated with RFID implementation is a figure originating in controlled retail deployments, most prominently the Hardgrave et al. Walmart RFID program studies; Bhardwaj et al. cite this figure in their scoping review in the context of healthcare supply chains [20], but primary evidence for healthcare-specific magnitudes of improvement remains less systematically documented and should be verified against site-level implementation data before being used in procurement business cases. Kumar et al. found that AI-based alerting in integrated supply chain platforms reduced the time taken to detect disruptions. Threshold alerts across heterogeneous streams of data cannot happen in the same time frame and scale as can be performed through digital-centric processes [5]. Nair et al. show that blockchain-enabled integrated supply chain platforms, when combined with predictive analytics, provide the data integrity and real-time visibility required for effective control towers in healthcare logistics [24].

For crisis response operations, control towers serve as the nerve center because they provide the shared data upon which cross-functional crisis response teams drive their response. In dynamic situations, it is important that response plans adapt dynamically to changing conditions using data from real-time data streams rather than from older data collected when a situation is detected. Research by MGI, conducted by the McKinsey Global Institute, finds that organizations with the infrastructure for real-time supply chain visibility are faster to mobilize their response to disruptions than those who depend on regular reporting cycles [16].



Figure 2: Digital Supply Chain Control Tower Architecture [2, 20, 23]

5.3 Adaptive Production Planning Systems

To maintain production continuity during active disruptions, the production planning system has to optimize the production plan under dynamically changing constraints. All classical production planning systems work with fixed planning horizons and stable assumptions about the inputs. For developing scheduling systems, Michael L. Pinedo proved that the ability to dynamically reschedule in reaction to changes in the real-time data, i.e., the ability to regenerate feasible schedules, is a required property of production systems that need to operate in turbulent environments [13]. In such environments, the availability of materials, the state of equipment, and the priorities of demand can change within hours after a feasible schedule has been developed.

Adaptive production planning systems solve this problem by leveraging real-time data feeds from inventory systems, supplier status, and demand signals in a continuously updated planning engine. They can also apply optimization techniques to design production schedules that maximize the production of priority products under constraints related to the availability of materials in the present and future. Badejo and Ierapetritou show that in the presence of disruptions and predefined product criticality hierarchies, adaptive scheduling considerably reduces the unmet demand for priority healthcare products [18]. As a more specific example of waiting penalties, an AI-enabled strong optimization approach (combining stochastic programming with distributionally strong optimization) was applied to healthcare resource pre-positioning and patient scheduling under uncertainty, with waiting penalties reduced by as much as 81.23% when adaptive plans were taken that minimized delay, transfer, and capacity overages simultaneously [5]. Product prioritization hierarchies, which can be defined based on pre-established medical criticality requirements, may be applied when capacity is not sufficient to be able to directly satisfy all production requests. When changes to the resulting production schedule require changes to the product sequence and facility change-overs, additional quality checks need to be implemented to ensure product quality and regulatory compliance before execution. The FDA's Drug Supply Chain Security Act also requires traceability to be continuous through manufacturing changes, meaning adaptive planning systems need to be designed and operate continuously, adhering to regulatory requirements without being a post-hoc verification step [17].

6. Resilient Manufacturing Network Framework

To summarize, the Resilient Manufacturing Network Framework developed in this paper brings together the analytical, operational, and governance elements described in the previous sections to offer one integrated architectural framework for active, holistic production. It consists of three interrelated layers: Predictive Risk Intelligence, Supplier Network Resilience, and Adaptive Production Operations. This architecture follows the Triple-A supply chain management principles laid out by Fu Jia et al. that argue agility, adaptability, and alignment must function as simultaneous and interconnected properties of resilient supply networks rather than as sequentially deployed capabilities [1].

The Predictive Risk Intelligence layer, which constitutes an anticipatory system, continuously monitors internal and external signals, simulates potential scenarios, and generates prioritized risk outputs to support operational decision-making. The Supplier Network Resilience layer is based on the digital supply chain twin methodology proposed by Ivanov and Dolgui that uses real-time operational data and simulation models to continuously update the scenario probabilities concerning disruptions [2]. It manages a portfolio of qualified, geographically dispersed suppliers, strategic buffer inventory, and supplier activation protocols. This layer's integrity determines which supply alternatives we should pursue when risk intelligence suggests that the disruption is underway or imminent.

The Adaptive Production Operations layer manages production scheduling, reallocates manufacturing capacity, and changes distribution based on inputs from the previous layers to ensure a continuous supply. It is in this layer where the risk intelligence and supply network resiliency derived from the previous three layers are translated into continuous output. The three layers loosely couple and operate in parallel, maintaining continuous communication through a shared data infrastructure. For example, a disruption alert raised within the risk intelligence layer will trigger the supplier network and the production planning layer in parallel. This allows for a faster reaction time compared to sequential escalation models: disruption escalation is faster in parallel than in sequence. Additionally, Christopher and Peck's work on responsive supply chain architectures aligns with this design approach [7].

A governance layer defines the organizational structure, the assignment of decision rights, and escalation procedures for activating and coordinating the three operational layers in case of disturbance. According to Piffari et al., governance integration is the most frequently neglected dimension of healthcare supply chain resilience frameworks. Technically skilled organizations repeatedly fail to translate analytical intelligence into coordinated operational response due to undefined decision authority and absent escalation protocols [19]. Technical capability, without governance integration, leads to analytical products that do not drive or support a coordinated response. Governance should therefore be considered as an architectural dimension.

6.1 Applied Disruption Scenario: Hurricane Helene and the IV Fluid Shortage (2024)

Real-world implications for operationalizing the Resilient Manufacturing Network Framework presented themselves in the aftermath of the September 2024 intravenous (IV) fluid shortage in the United States. Baxter's International North Cove, North Carolina, plant, responsible for 60% of IV fluid supply, was directly impacted by Hurricane Helene flooding that caused catastrophic damage and production disruption. A national shortage of saline solution, lactated Ringer's solution, and parenteral nutrition products occurred within days. Shortages as a whole also highlighted the compounding effect of the structural weaknesses discussed in sections 2 and 3: geographic concentration of critical production, limited alternative qualified sources of FDA-regulated parenteral production, and specialty infrastructure not readily convertible for other products.

Using the three-layer framework as a lens to examine this event provides insight into how the potential value of the preceding three layers was realized and where it was not. For example, at the Predictive Risk Intelligence level, the NHC predicted the track of the storm 72-96 hours before landfall over western North Carolina. A risk intelligence system that ingests National Weather Service severe event feeds and cross-references them with facility locations would have flagged the North Cove facility as at risk. Scenario modeling a pre-built parenteral fluid manufacturing "single-site production failure" template would have yielded an estimated inventory depletion timeline for the top ten affected products in the hours following the weather alert. This would have given hospital systems and procurement organizations visibility into the likely depth of shortages upfront. As a result, hospital procurement teams only find out the full extent of shortages when notices of product allocation are sent from distributors, when the leeway and scope for action are dramatically diminished.

At the Supplier Network Resilience layer, an important structural gap was the absence of pre-qualified alternative manufacturers for high-volume parenteral products. FDA qualification requirements for parenteral drug manufacturing are among the most stringent in the world, so it would take twelve to eighteen months to qualify a new site under normal circumstances. The FDA's emergency use authorization process allowed accelerated qualification of manufacturing sites abroad, including in Ireland and China, but this process still would have taken weeks. A manufacturer with a second source and manufacturing site pre-qualified in an alternate geographic area outside the Appalachian region affected by the flood would have been able to ramp up production to meet demand in days. Using conservative estimates of the revenue and clinical impact (deferred surgical procedures and rationed product in the intensive care unit) of the shortage, the costs associated with the lack of a pre-qualified second source were substantially higher than the annualized costs of maintaining one throughout the shortage.

In the Adaptive Production Operations layer, hospitals and health systems had to implement their own adaptive prioritization strategies, rationing IV fluids by clinical criticality and substituting oral hydration according to medically appropriate guidelines. In contrast, manufacturers that had adaptive planning systems could have used the remaining inventory to optimize across customer segments based on medical criticality tier, extending the supply to the highest-need clinical context for the longest period of time. Without such systems, distributor inventory managers made allocation decisions based on their judgment rather than on clinical priorities.

In the years following the Hurricane Helene IV fluid shortage, the FDA and HHS cited the Hurricane Helene IV event as a case study of concentration risk associated with reliance on a single-source supplier for an essential medical product [23]. After the Hurricane Helene IV event, FDA guidance on medical product supply chain resilience listed single-site concentration in parenteral manufacturing as a structural vulnerability. This is the same vulnerability addressed in the Supplier Network Resilience layer of the Framework.

7. Societal and Strategic Implications

In healthcare, the resilience of the supply chain must go beyond what is possible for individual organizations, because the ability of the public health system to adapt to surprises largely depends on the ability of manufacturers of essential medical products to adapt and handle those surprises. The United Nations Sustainable Development Goals (SDG) Report 2022 identified health infrastructure and supply chains as key enablers and determinants of SDG 3 (Good Health and Well-Being) and indicated that supply chain failures during health emergencies disproportionately affect low and middle-income populations that lack access to alternative sources of essential medical products [15].

Production failures during public health emergencies restrict the output of diagnostics, therapeutics, and nutritional products when demand is at its highest and the population is most vulnerable. The emergence of fake medicines is one of the most important potential problems for society during public health emergencies. According to Alfaouri et al., this is a global problem, but the impact in developed and developing countries is very different from each other's. In developed countries, counterfeit medicines account for less than 1% of the pharmaceutical market. That can reach 30% of medicines in developing countries, which is a discrepancy expected partly because product-quality enforcement is less stringent and counterfeits are easier to infiltrate supply chains [21]. The systematic review by Alfaouri et al. also observed that the downstream effects of the supply chain on treatment pathways are greater in resource-poor healthcare systems, and that the costs of incorrect supply chains are borne disproportionately by those least able to bear the cost [21]. This policy rationale creates a framework for regulations that encourage investment in pre-competitive resilience measures such as multi-source supplier qualification and calculated material reserves where products are designated as medically essential. At the planned level, a resilient supply chain can deliver a sustained competitive advantage. A report from the McKinsey Global Institute found that resilient companies experienced more continuity of revenue if their supply networks were disrupted and greater share gain if their competitors' production was interrupted [16]. According to the US Department of Health and Human Services (HHS) measures for resilience, criticality, and vulnerability of the healthcare supply chain, procurement organizations in the public sector expect measurable resilience performance from medical product suppliers, and resilience investment is expected to play a key role in calculated healthcare procurement contracts [23]. Therefore, we should compare the calculated payoff of resilience infrastructure projects with the value of avoided operational risk.

Conclusion

Supply chains designed around efficiency without explicit resilience criteria embed fragilities; these only appear when the regularity and assumptions of the stable state are ruptured by a disruption. The failures triggered under this scenario (production halts, shortage cascades, and counterfeit infiltration) can be anticipated and should be designed for, meaning resilience should be an architectural principle and not an afterthought. To succeed in resilient manufacturing, this article proposes the Resilient Manufacturing Network Framework. The framework reorients manufacturing organizations and enables their resilience through three mutually reinforcing levers: predictive risk intelligence, multi-supplier networks, and adaptive production planning. No single lever is sufficient. Performance at the system level can only be achieved if all three layers work together, using shared digital infrastructure, to deliver the real-time visibility and situational awareness required under the framework. Section 6A provides one example of the challenge. The Hurricane Helene case shows that missing any of these layers at any point in the supply chain could mean a regional weather event becomes a national clinical supply chain failure. Healthcare manufacturers that embed the required capabilities into operating models will increase their chances of both maintaining manufacturing continuity when a large-scale disruption occurs and protecting their planned performance and the public health systems that depend on them.

References

[1] Fu Jia et al., "Triple A supply chain management and sustainability," Industrial Management & Data Systems 125, no. 10 (2025): 2725–2752. Available: https://doi.org/10.1108/IMDS-10-2023-0756

[2] Dmitry Ivanov and Alexandre Dolgui, "A digital supply chain twin for managing the disruption risks and resilience in the era of Industry 4.0," Production Planning & Control 32, no. 9 (2021): 775–788. Available: https://www.tandfonline.com/action/showCitFormats?doi=10.1080/09537287.2020.1768450

[3] European Medicines Agency, "Good manufacturing practice." (n.d.). Available: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice

[4] World Health Organization, "Global surveillance and monitoring system for substandard and falsified medical products: activity report, August 2017–December 2021," 2024. Available: https://www.who.int/publications/i/item/9789240097513

[5] Vikas Kumar et al., "Artificial intelligence applications in healthcare supply chain networks under disaster conditions," International Journal of Production Research 63, no. 2 (2025): 395–403. Available: https://www.tandfonline.com/doi/pdf/10.1080/00207543.2024.2444150

[6] David Simchi-Levi et al., "Supply Chain Competition and Collaboration Models," in The Logic of Logistics: Theory, Algorithms, and Applications for Logistics Management, pp. 213–228. New York, NY: Springer New York, 2013. Available: https://link.springer.com/chapter/10.1007/978-1-4614-9149-1_11

[7] Martin Christopher and Helen Peck, "Building the resilient supply chain," International Journal of Logistics Management, 2004. Available: https://dspace.lib.cranfield.ac.uk/server/api/core/bitstreams/6ce1ceca-e8c6-4b37-8f26-6fdbe3c08a8a/content

[8] Sunil Chopra and M. S. Sodhi, "Supply-chain breakdown," MIT Sloan Management Review 46, no. 1 (2004): 53–61. Available: https://d1wqtxts1xzle7.cloudfront.net/34808711/Supply_chain_Break_down-libre.pdf

[9] Thomas H. Davenport and Rajeev Ronanki, "Artificial intelligence for the real world," Harvard Business Review 96, no. 1 (2018): 108–116. Available: https://academichelptoday.com/assets/documents/Artificial_Intelligence_for_the_Real_World_-_HBR.pdf

[10] Maciel M. Queiroz et al., "Impacts of epidemic outbreaks on supply chains: mapping a research agenda amid the COVID-19 pandemic through a structured literature review," Annals of Operations Research 319, no. 1 (2022): 1159–1196. Available: https://link.springer.com/content/pdf/10.1007/s10479-020-03685-7.pdf

[11] Paul H. Zipkin, “Foundations of Inventory Management,” New York: McGraw Hill, 2000. Available: https://sutlib2.sut.ac.th/sut_contents/H105195.pdf

[12] Steven Nahmias, "Perishable inventory theory: A review," Operations Research 30, no. 4 (1982): 680–708. Available: https://www.researchgate.net/profile/Steven-Nahmias/publication/12999281_Perishable_Inventory_Theory_A_Review

[13] Michael L. Pinedo, "Design and implementation of scheduling systems: More advanced concepts," in Scheduling: Theory, Algorithms, and Systems, pp. 485–508. Cham: Springer International Publishing, 2016. Available: https://link.springer.com/chapter/10.1007/978-3-319-26580-3_18

[14] Elaine Dezenski, "Building supply chain resilience," World Economic Forum, 2012. Available: https://www.weforum.org/stories/2012/09/building-supply-chain-resilience/

[15] United Nations, "The Sustainable Development Goals Report 2022," 2022. Available: https://unstats.un.org/sdgs/report/2022/

[16] McKinsey Global Institute, "Risk, resilience, and rebalancing in global value chains," 2020.

Available: https://www.mckinsey.com/~/media/mckinsey/business%20functions/operations/our%20insights/risk-resilience-and-rebalancing-in-global-value-chains-full-report-vh.pdf

[17] U.S. Food and Drug Administration, "Drug Supply Chain Security Act (DSCSA)," 2025. Available: https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa

[18] Oluwadare Badejo and Marianthi Ierapetritou, "Enhancing pharmaceutical supply chain resilience: A multi-objective study with disruption management," Computers & Chemical Engineering 188 (2024): 108769. Available: https://www.sciencedirect.com/science/article/abs/pii/S009813542400187X

[19] Claudia Piffari et al., "Challenges in Healthcare Supply Chain Resilience Management: A Conceptual Framework," IFAC-Papers On Line 58, no. 19 (2024): 1126–1131. Available: https://www.sciencedirect.com/science/article/pii/S2405896324015246

[20] Pankaj Bhardwaj et al., "Resilience in Public Healthcare Supply Chain Management: A Scoping Review from Indian Perspective," DY Patil Journal of Health Sciences 13, no. 2 (2025): 89–95. Available: https://journals.lww.com/dypj/fulltext/2025/04000/resilience_in_public_healthcare_supply_chain.1.aspx

[21] Mustafa Alfaouri et al., "Pharmaceutical supply chain management challenges in developing countries: a systematic literature review," Journal of African Business 26, no. 4 (2025): 798–841. Available: https://www.tandfonline.com/doi/pdf/10.1080/15228916.2025.2532943

[22] C. López et al., "Modeling supply chain disruptions due to geopolitical reasons: A systematic literature review," Transportation Research Part E: Logistics and Transportation Review 202 (2025): 104290. Available: https://www.sciencedirect.com/science/article/pii/S136655452500331X

[23] U.S. Department of Health and Human Services, "Defining and Measuring the Resilience, Criticality, and Vulnerability of Medical Product Supply Chains," 2025. Available: https://aspe.hhs.gov/reports/measuring-supply-chain-resilience

[24] Raji Ramakrishnan Nair et al., "Predictive BlockVax distribution: Enhancing healthcare supply chain resilience with blockchain and LSTM," International Journal of Computational Intelligence Systems 18, no. 1 (2025): 159. Available: https://link.springer.com/content/pdf/10.1007/s44196-025-00897-2.pdf

[25] ManMohan S. Sodhi and Christopher S. Tang, "Managing Supply Chain Risk," Springer International Publishing, 2012. Available: https://doi.org/10.1007/978-1-4614-3238-8